Author(s):
Amol Pawar, Chetan Salunke, Kailaspati Chittam, Anita B. Patil
Email(s):
amolraje957@gmail.com
DOI:
10.5958/0975-4377.2020.00008.7 
Address:
Amol Pawar1*, Chetan Salunke2, Kailaspati Chittam2, Anita B. Patil3
1Department of Quality Assurance KVPSS Institute of Pharmaceutical Education, Boradi Tal-Shirpur, Dist-Dhule (M.S.) India 425-405.
2Department of Pharmacognosy, Annasaheb Ramesh Ajmera College of Pharmacy Nagao Dhule, Dist: Dhule 424002, Maharashtra, India.
3Department of Clinical Pharmacy. R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur, Dist.: Dhule (M.S.) India 425-405.
*Corresponding Author
Published In:
Volume - 12,
Issue - 2,
Year - 2020
ABSTRACT:
Chronic hepatitis C is a slowly progressive liver disease that may evolve into cirrhosis with its potential complications of liver failure or hepatocellular carcinoma. Current therapy with a interferon is directed at viral clearance, but sustained response is only achieved in 20–40% of patients without cirrhosis, and less than 20% in patients with cirrhosis who have the greatest need for therapy. Treatment for those who do not respond to anti-viral therapy is highly desirable. In Japan glycyrrhizin has been used for more than 20 years as treatment for chronic hepatitis. In randomized controlled trials, glycyrrhizin induced a significant reduction of serum aminotransferases and an improvement in liver histology compared to placebo. Recently, these short-term effects have been amplified by a well conducted retrospective study suggesting that long-term usage of glycyrrhizin prevents development of hepatocellular carcinoma in chronic hepatitis C. The mechanism by which glycyrrhizin improves liver biochemistry and histology are undefined. Metabolism, pharmacokinetics, side-effects, and anti-viral and hepatoprotective effects of glycyrrhizin are discussed.
Cite this article:
Amol Pawar, Chetan Salunke, Kailaspati Chittam, Anita B. Patil. Development of an Analytical Method of Glycyrrhizin by using High Pressure Liquid Chromatography. Res. J. Pharma. Dosage Forms and Tech.2020; 12(2): 49-52. doi: 10.5958/0975-4377.2020.00008.7